Stefaan Vandorpe, Jan De Houwer, Tom Beckers
Further evidence for the role of inferential reasoning in forward blocking
Memory & cognition
people living hiv plwh multidrugresistant mdr viruses limited therapeutic options present challenges regarding clinical management recent studies shown passive transfer combination broadly neutralizing antibodies bnabs hiv antidomain 1 cd4 antibody ub421 sustain virologic suppression plwh absence antiretroviral therapy art yet studies addressing therapeutic potential antibodies andor detailed characterization immunologic virologic parameters plwh mdr hiv lacking examined levels immune activation exhaustion markers cd8 cells intact hiv proviral dna burden 11 plwh mdr viruses comparison purposes included control group consisting 27 artnave viremic plwh addition determined sensitivity infectious viral isolates obtained participants eight bnabs 3bnc117 101074 vrc01 vrc07 n6 10e8 pgdm1400 pgt121 two anticd4 antibodies ibalizumab ub421 using tzmblbased neutralizationsuppression assay level intact hiv proviral dna comparable two groups p 029 levels activation exhaustion markers pd1 p 00019 tigit p 00222 2b4 p 00015 cd160 p 00015 cd38hladr p 00138 significantly lower mdr group infectious viral isolates study participant mdr hiv resistant least 2 bnabs however sensitive least one cd4binding noncd4binding site antibodies majority participants ibalizumabsensitive viruses although isolates participants showed reduced sensitivity ibalizumab notably none 93 viral isolates obtained participants resistant ub421 data suggest combination therapy hivspecific bnabs andor ub421 presence optimized background therapy could potentially provide sustained virologic suppression plwh mdr hiv however therapeutic strategy needs evaluated human clinical trials division intramural research national institute allergy infectious diseases national institutes health